Literature DB >> 4522169

Antihypertensive effect of spironolactone in essential, renal and mineralocorticoid hypertension.

F Mantero, D Armanini, S Urbani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4522169     DOI： 10.1042/cs045219s

Source DB:  PubMed          Journal:  Clin Sci Mol Med Suppl        ISSN： 0144-4107


× No keyword cloud information.
  3 in total

1.  Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.

Authors:  D Armanini; C Scaroni; M J Mattarello; C Fiore; N Albiger; P Sartorato
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

2.  Influence of spironolactone on serum corticosteroids in primary hyperaldosteronism.

Authors:  U Abshagen; S Spörl; W Oelkers
Journal:  Klin Wochenschr       Date:  1979-02-15

3.  Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism.

Authors:  A Ulmann; C Bertagna; A Le Go; J M Husson; A Tache; P Sassano; J Menard; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.